Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of derazantinib monotherapy or
derazantinib in combination with paclitaxel, ramucirumab, or atezolizumab in patients with
HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR2
genetic aberrations (GA).